Literature DB >> 16574040

Counting the costs of overweight and obesity: modeling clinical and cost outcomes.

Daniel M D Tucker1, Andrew J Palmer, William J Valentine, Stéphane Roze, Joshua A Ray.   

Abstract

OBJECTIVE: To quantify changes in clinical and cost outcomes associated with increasing levels of body mass index (BMI) in a US setting. RESEARCH METHODS AND PROCEDURES: A semi-Markov model was developed to project and compare life expectancy (LE), quality-adjusted life expectancy (QALE) and direct medical costs associated with distinct levels of BMI in simulated adult cohorts over a lifetime horizon. Cohort definitions included age (20-65 years), gender, race, and BMI (24-45 kg m(-2)). Cohorts were exclusively male or female and either Caucasian or African-American. Mortality rates were adjusted according to these factors using published data. BMI progression over time was modeled. BMI-dependent US direct medical costs were derived from published sources and inflated to year 2004 values. A third party reimbursement perspective was taken. QALE and costs were discounted at 3% per annum.
RESULTS: In young Caucasian cohorts LE decreased as BMI increased. However, in older Caucasian cohorts the BMI associated with greatest longevity was higher than 25 kg m(-2). A similar pattern was observed in young adult African-American cohorts. A survival paradox was projected in older African-American cohorts, with some BMI levels in the obese category associated with greatest longevity. QALE in all four race/gender cohorts followed similar patterns to LE. Sensitivity analyses demonstrated that simulating BMI progression over time had an important impact on results. Direct costs in all four cohorts increased with BMI, with a few exceptions.
CONCLUSIONS: Optimal BMI, in terms of longevity, varied between race/gender cohorts and within these cohorts, according to age, contributing to the debate over what BMI level or distribution should be considered ideal in terms of mortality risk. Simulating BMI progression over time had a substantial impact on health outcomes and should be modeled in future health economic analyses of overweight and obesity.

Entities:  

Mesh:

Year:  2006        PMID: 16574040     DOI: 10.1185/030079906X96227

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

1.  Obesity and medicare expenditure: accounting for age-related height loss.

Authors:  Nneka C Onwudiwe; Bruce Stuart; Ilene H Zuckerman; John D Sorkin
Journal:  Obesity (Silver Spring)       Date:  2010-07-22       Impact factor: 5.002

2.  Methodological Challenges in Estimating the Lifetime Medical Care Cost Externality of Obesity.

Authors:  Robert C Schell; David R Just; David A Levitsky
Journal:  J Benefit Cost Anal       Date:  2021-07-27

Review 3.  Direct medical cost of overweight and obesity in the USA: a quantitative systematic review.

Authors:  A G Tsai; D F Williamson; H A Glick
Journal:  Obes Rev       Date:  2011-01       Impact factor: 9.213

4.  Body mass index and lifetime healthcare utilization.

Authors:  Christina Hansen Edwards; Eline Aas; Jonas Minet Kinge
Journal:  BMC Health Serv Res       Date:  2019-10-15       Impact factor: 2.655

5.  Healthcare utilisation in overweight and obese children: a systematic review and meta-analysis.

Authors:  Taimoor Hasan; Tom S Ainscough; Jane West; Lorna Katharine Fraser
Journal:  BMJ Open       Date:  2020-10-08       Impact factor: 2.692

Review 6.  Health Economic Aspects of Childhood Excess Weight: A Structured Review.

Authors:  Olu Onyimadu; Mara Violato; Nerys M Astbury; Susan A Jebb; Stavros Petrou
Journal:  Children (Basel)       Date:  2022-03-24

7.  An Analysis of the Medical Costs of Obesity for Fifth Graders in California and Texas.

Authors:  Danielle E Levitt; Allen W Jackson; James R Morrow
Journal:  Int J Exerc Sci       Date:  2016-01-15

8.  Impact of overweight and obesity on life expectancy, quality-adjusted life years and lifetime costs in the adult population of Ghana.

Authors:  Stella Lartey; Lei Si; Thomas Lung; Costan G Magnussen; Godfred O Boateng; Nadia Minicuci; Paul Kowal; Alison Hayes; Barbara de Graaff; Leigh Blizzard; Andrew J Palmer
Journal:  BMJ Glob Health       Date:  2020-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.